Drug Profile
Research programme: Anti-bacterial therapeutics - Sumitomo Pharma
Latest Information Update: 05 Apr 2022
Price :
$50
*
At a glance
- Originator Questcor Pharmaceuticals
- Developer Sumitomo Pharma
- Class Diterpenes
- Mechanism of Action Enzyme inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections